{"id":505441,"date":"2021-06-22T08:31:04","date_gmt":"2021-06-22T12:31:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\/"},"modified":"2021-06-22T08:31:04","modified_gmt":"2021-06-22T12:31:04","slug":"eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\/","title":{"rendered":"Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform"},"content":{"rendered":"

<\/p>\n

Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform<\/b><\/p>\n

VICTORIA, British Columbia–(BUSINESS WIRE<\/a>)–
\nIMMUNOPRECISE ANTIBODIES LTD (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) the market leader in full-service therapeutic discovery and development and Eurofins Discovery, the leading provider of products and services to the drug discovery industry and a Eurofins Scientific (Paris:ERF) company, announced a commercial collaboration. Leveraging complementary strengths in Eurofins Discovery\u2019s in vitro pharmacology services and ImmunoPrecise\u2019s in vivo characterization and discovery technologies, this collaboration provides greater access to solutions that empower scientists to pursue life-changing medicines in a diverse range of indications.\n<\/p>\n

This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20210622005118\/en\/<\/a><\/p>\n

\nEurofins Discovery\u2019s global clients will have access to ImmunoPrecise\u2019s end-to-end antibody discovery capabilities using wild type and best-in-class in vivo antibody discovery technologies that are optimized to deeply mine antibody repertoires. This collaboration supports Eurofins Discovery\u2019s biotherapeutics strategy to extend their capacity and capability to develop new biologic entities, guiding clients from target validation through preclinical development, production, and beyond with the expertise required to address the unique challenges of each discovery project.\n<\/p>\n

\nAs the leading global innovation-driven and customer-focused providers, Eurofins Discovery and ImmunoPrecise share common values in the culture of collaboration and the unrelenting pursuit of service excellence.\n<\/p>\n

For further information<\/b><\/p>\n

www.eurofinsdiscoveryservices.com<\/a><\/p>\n

About Eurofins Discovery<\/b><\/p>\n

\nEurofins Discovery has supported Drug Discovery research for over 40 years. Eurofins is recognized as the industry leader for providing drug discovery researchers the largest and most diverse portfolio of standard and custom in vitro safety & pharmacology assays and panels for drug screening and profiling. In addition to in vitro safety pharmacology strengths, we also offer a broad portfolio of over 3500 drug discovery services and 1800 products. These include in vitro assays, cell-based phenotypic assays, safety pharmacology and efficacy, ADME toxicology, medicinal chemistry design, synthetic chemistry, and custom proteins and assay development capabilities. We support a variety of drug discovery targets such as GPCRs, Kinases, Ion Channels, Nuclear Hormone Receptors and other proteins & enzymes. The Eurofins Discovery capabilities, expertise, knowledge and skill sets enable the company to provide clients the benefit of being able to work with a single outsourcing provider (CRO) for all their drug discovery programs.\n<\/p>\n

About Eurofins \u2013 the global leader in bio-analysis<\/b><\/p>\n

\nEurofins is Testing for Life. Eurofins is the global leader in food, environment, and pharmaceutical product testing. It is also one of the market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing.\n<\/p>\n

\nWith over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins\u2019 companies offer a portfolio of over 200,000 analytical methods.\n<\/p>\n

\nEurofins Shares are listed on Euronext Paris Stock Exchange.\n<\/p>\n

About ImmunoPrecise Antibodies<\/b><\/p>\n

\nImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company aims to transform the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and\/or challenging epitopes. For further information, visit www.immunoprecise.com<\/a> or contact solutions@immunoprecise.com<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210622005118\/en\/<\/a><\/span><\/p>\n

\nMedia:
\n
Aida Yodites, Director Marketing Communications
\n
AidaYodites@eurofinsus.com<\/a><\/p>\n

\nInvestors:
\n
LifeSci Advisors
\n
John Mullaly
\n
Email: jmullaly@lifesciadvisors.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Canada<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Other Health Health Pharmaceutical Oncology Other Science Research Infectious Diseases Genetics Science Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform VICTORIA, British Columbia–(BUSINESS WIRE)– IMMUNOPRECISE ANTIBODIES LTD (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) the market leader in full-service therapeutic discovery and development and Eurofins Discovery, the leading provider of products and services to the drug discovery industry and a Eurofins Scientific (Paris:ERF) company, announced a commercial collaboration. Leveraging complementary strengths in Eurofins Discovery\u2019s in vitro pharmacology services and ImmunoPrecise\u2019s in vivo characterization and discovery technologies, this collaboration provides greater access to solutions that empower scientists to pursue life-changing medicines in a diverse range of indications. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20210622005118\/en\/ Eurofins Discovery\u2019s global clients will have access to ImmunoPrecise\u2019s … <\/p>\n

Continue reading “Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-505441","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform VICTORIA, British Columbia–(BUSINESS WIRE)– IMMUNOPRECISE ANTIBODIES LTD (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) the market leader in full-service therapeutic discovery and development and Eurofins Discovery, the leading provider of products and services to the drug discovery industry and a Eurofins Scientific (Paris:ERF) company, announced a commercial collaboration. Leveraging complementary strengths in Eurofins Discovery\u2019s in vitro pharmacology services and ImmunoPrecise\u2019s in vivo characterization and discovery technologies, this collaboration provides greater access to solutions that empower scientists to pursue life-changing medicines in a diverse range of indications. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20210622005118\/en\/ Eurofins Discovery\u2019s global clients will have access to ImmunoPrecise\u2019s … Continue reading "Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-22T12:31:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210622005118r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform\",\"datePublished\":\"2021-06-22T12:31:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\\\/\"},\"wordCount\":622,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210622005118r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\\\/\",\"name\":\"Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210622005118r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-06-22T12:31:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210622005118r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210622005118r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\/","og_locale":"en_US","og_type":"article","og_title":"Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform - Market Newsdesk","og_description":"Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform VICTORIA, British Columbia–(BUSINESS WIRE)– IMMUNOPRECISE ANTIBODIES LTD (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) the market leader in full-service therapeutic discovery and development and Eurofins Discovery, the leading provider of products and services to the drug discovery industry and a Eurofins Scientific (Paris:ERF) company, announced a commercial collaboration. Leveraging complementary strengths in Eurofins Discovery\u2019s in vitro pharmacology services and ImmunoPrecise\u2019s in vivo characterization and discovery technologies, this collaboration provides greater access to solutions that empower scientists to pursue life-changing medicines in a diverse range of indications. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20210622005118\/en\/ Eurofins Discovery\u2019s global clients will have access to ImmunoPrecise\u2019s … Continue reading \"Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-22T12:31:04+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210622005118r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform","datePublished":"2021-06-22T12:31:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\/"},"wordCount":622,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210622005118r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\/","name":"Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210622005118r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-06-22T12:31:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210622005118r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210622005118r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/505441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=505441"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/505441\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=505441"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=505441"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=505441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}